Dutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate Biopsy Increases Prostate Cancer Detection
|
|
- Joella McCoy
- 5 years ago
- Views:
Transcription
1 european urology 53 (2008) available at journal homepage: Prostate Cancer Dutasteride Prior to Contrast-Enhanced Colour Doppler Ultrasound Prostate Biopsy Increases Prostate Cancer Detection Michael Mitterberger a, *, Germar Pinggera a, Wolfgang Horninger a, Hannes Strasser a, Ethan Halpern b, Leo Pallwein a, Johann Gradl a, Georg Bartsch a, Ferdinand Frauscher a a Departments of Urology and Radiology II, Medical University Innsbruck, Innsbruck, Austria b Division of Diagnostic Ultrasound, Thomas Jefferson University, Philadelphia, PA, USA Article info Article history: Accepted February 9, 2007 Published online ahead of print on February 20, 2007 Keywords: Dutasteride Contrast-enhanced colour Doppler ultrasound Prostate biopsy Abstract Objectives: This study assessed the effect of premedication with dutasteride, a dual 5a-reductase inhibitor, on prostatic blood flow prior to prostate biopsy and its impact on prostate cancer detection. Methods: Thirty-six patients, aged yr, with elevated prostatespecific antigen (PSA) levels (1.25 ng/ml and free-to-total ratio of <18%) were treated with dutasteride 14 d prior to prostate biopsy. Contrast-enhanced colour Doppler (CECD) ultrasound was performed before and 7 and 14 d after dutasteride treatment. Contrast-enhanced targeted biopsies (5) were performed into hypervascular areas of the peripheral zone only. Subsequently, a second investigator performed 10 systematic biopsies of the prostate in a standard spatial distribution guided by conventional grey-scale ultrasonography on a Combison 530MT unit. Results: Dutasteride reduced prostatic blood flow in benign prostatic tissue, whereas in prostate cancer areas blood flow was still observed after a 14-d course of dutasteride intake. A reduction of blood flow was observed even after 7 d. Maximum flow reduction was observed after 14 d. Twelve patients (33%) of our cohort were found to have suspicious blood flow and prostate cancer and six cancers (17%) were detected solely by targeted contrast-enhanced biopsy. Conclusion: Premedication with dutasteride seems promising to improve prostate cancer detection by using CECD ultrasound. # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. * Corresponding author. Department of Urology, Medical University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. Tel ; Fax: address: michael.mitterberger@uibk.ac.at (M. Mitterberger) /$ see back matter # 2007 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo
2 european urology 53 (2008) Introduction Systematic prostate biopsy under ultrasound (US) guidance is the preferred diagnostic method for prostate cancer detection [1]. However, US-guided detection of prostate cancer is limited by the inability of conventional grey scale and Doppler sonography to adequately distinguish benign and malignant prostate tissue [2,3]. In several recently published papers, an improved detection of prostate cancer based on contrast-enhanced colour Doppler (CECD) over grey scale sonography was reported [4,5]. Because of the increased local angiogenesis associated with cancer of the prostate, improved cancer detection may be achieved on the basis of the CECD blood flow characteristics of prostate cancer [4,5]. But prostatitis and benign prostatic hyperplasia (BPH) are also associated with increased CECD flow. Dutasteride (Avodart 1 ; Glaxo-Smith-Kline, Philadelphia, PA, USA), a type 1/2 5a-reductase inhibitor, is approved for treatment of symptomatic BPH. As recent studies suggest, dutasteride can reduce blood flow in normal prostate tissue and BPH. By reducing flow in normal tissues that responds to the 5a-reductase inhibitor it seems to be possible to improve differentiation between benign tissue and cancer in the prostate [6,7]. The theory was based on the fact that dutasteride should reduce blood flow in normal, benign prostate tissue, whereas blood flow in cancer should not be influenced and therefore prostate cancer detection should be improved. The primary objectives were to demonstrate a qualitative reduction in the CECD flow signal from normal prostate after treatment with dutasteride and to further determine the minimum length of treatment necessary to inhibit CECD flow in the normal prostate and in BPH tissue. Finally, we hoped to demonstrate that the identification of malignant tissue by increased CECD flow patterns can be improved after treatment with dutasteride. Therefore, the goal of this study was to assess the effect of premedication with dutasteride on prostatic blood flow prior to prostate biopsy and the impact on prostate cancer detection. 2. Patients and methods 2.1. Study patients We examined 36 consecutive asymptomatic screening male volunteers with a serum total prostate-specific antigen (PSA) level 1.25 ng/ml and a free-to-total PSA ratio <18% (Tyrolean PSA Screening Project). Digital rectal examination was not part of the screening process in this study, although it was done directly before biopsy. The patients were yr of age (mean, 56 yr). Study exclusion criteria were active urinary tract infection or contraindications to the US contrast agent Sonovue TM (Bracco, Milano, Italy). The study was approved by our institutional review board and written patient informed consent was obtained before the examination Medication Dutasteride capsules (0.5 mg) were given to patients in 2-wk supplies. Patients were instructed to take one tablet orally each day starting immediately after the baseline US study. Medication was continued until the day of biopsy US procedure US was performed with the patients in the lithotomy position with a Sequoia system (Siemens Medical Systems, Mountain View, CA, USA) and an EC10C5 end-fire probe. Doppler imaging was performed at the 9-MHz frequency setting. Transverse images of the prostate were obtained by sweeping from the base to the apex of the gland. Doppler gain settings were left at their default values for all studies. Default system settings were adjusted during the baseline examination to maximise the visualisation of colour flow within the prostate without producing colour noise in stationary tissue. The same settings were used during followup examinations. First the CECD US flow within the whole prostate was assessed as described by Leventis et al [8]. Then the flow pattern was divided in radial or irregular and into symmetrical or asymmetrical flow. Than CECD US flow within the prostate was subjectively scored during each study. Flow was scored by using a 4-point scale in which a score of 0 indicated no flow; a score of 1, diminished flow; a score of 2, normal flow; and a score of 3, increased flow. Each patient started taking 0.5 mg dutasteride/d immediately after the baseline US study and returned weekly for repeat US and Doppler evaluation of the prostate. On each return visit, Doppler flow was evaluated with transrectal US and subjectively scored Biopsy procedure The night before biopsy all participants began a 5-d course of a fluoroquinolone antibiotic or appropriate alternative antibiotic if they had a fluoroquinolone allergy. A cleansing enema was administered on the morning of biopsy. Patients were instructed not to ingest aspirin or nonsteroidal anti-inflammatory agents for at least 10 d before biopsy. CECD and the SB were performed using a needle guidance device with the patient in the lithotomy position. One investigator used CECD imaging with an Acuson Sequoia 512 unit (Siemens Medical Solutions) fitted with an end-fire probe operating at a Doppler frequency of 9 MHz. Up to five targeted biopsy cores were obtained during intravenous injection of the US contrast agent Sonovue (Bracco), using a maximum dose of 2 ml. The contrast agent was prepared in standard fashion. Colour Doppler system presets were optimised based on experience to detect contrast-enhanced
3 114 european urology 53 (2008) flow. Contrast-enhanced imaging was always performed before systematic biopsies (SBs) to avoid biopsy-induced hyperaemia on the contrast-enhanced imaging study. CECD was performed into a maximum of two hypervascular areas in the peripheral zone (PZ) only. No targeted biopsies were performed in the transition zone (TZ). This biopsy approach was done using a 9-MHz end-fire probe, which enables a single plane approach. Subsequently another investigator blinded to contrastenhanced findings performed 10 SBs in standard spatial distribution. This biopsy was guided by grey-scale US using an endorectal probe unit fitted with a biplane probe operating at a grey scale frequency of 7.5 MHz (BK-med, Copenhagen, Denmark). Biopsies were obtained without regard to prostate US appearance. Two biopsy cores per side were obtained from the apex area, including one medial and one lateral. Another biopsy core was obtained on each side from the lateral aspect of the mid prostate, one was obtained on each side from the posterolateral area at the base, and a final biopsy core was obtained from each side of the TZ. TZ biopsies were anterior biopsies in the mid prostate. Biopsies were obtained transrectally using an 18-gauge biopsy needle. Each biopsy core was reviewed by a pathologist and reported as cancer with an assigned Gleason score, or as prostatic intraepithelial neoplasia, inflammation, or benign prostatic tissue. The changes in prostatic blood flow and the impact on prostate cancer detection were evaluated. For statistical analyses the Wilcoxon matched-pairs signed rank test was used; p < 0.05 was considered to indicate a statistically significant difference. 3. Results 3.1. Biopsies Mean patient age was 56 yr (range: yr), mean total PSA was 4.6 ng/ml (range: ng/ ml), the mean free-to-total PSA ratio was 12.83% (range: %), and mean prostate volume was 35.5 ml (range: ) CECD flow suppression In all patients a suppression of CECD flow by at least one score was noted after 1 wk of dutasteride therapy ( p < 0.02). After 2 wk of dutasteride therapy CECD flow was further suppressed one score in all patients ( p = 0.03), as shown in Fig Cancer detection In 12 patients (33.3%) of our cohort of 36 patients prostate cancer was found. Pathologic evaluation revealed that the areas of malignancy had a Gleason score of 6 in six patients, Gleason score of 7 in three patients, and a Gleason score of 8 in three patients. CECD-targeted biopsy revealed cancer in all 12 of these patients. SBs revealed the tumour in 6 of the 12 patients. Cancer was detected in 30 (17%) of 180 CECD-targeted biopsy cores and in 36 (10%) of 360 SB cores. In the 12 patients with cancer, conditional logistic regression analysis revealed that targeted cores were twice as more likely to be positive for cancer ( p = 0.027). Prostatitis was diagnosed at biopsy in 12 patients. None of these patients were also diagnosed with cancer. The rate of prostatitis detection was in SB cores was 40 of 360 (11%), whereas in CECD-directed biopsy prostatitis was diagnosed in 9 of 180 (5%). Dutasteride reduced prostatic blood flow in benign prostatic tissue, whereas in prostate cancer areas blood flow was still observed after a 14-d course of dutasteride intake. The sites of cancer were more obvious after dutasteride therapy (Fig. 1B and C) Complications No adverse events were reported. No complications resulted from the medication, US examinations, or biopsy procedures. 4. Discussion Transrectal US-guided SB of the prostate is the standard technique for diagnosing prostate cancer [1]. Several clinical studies have demonstrated the efficacy of contrast-enhanced US imaging for the detection of prostate cancer [4,5]. In this study patients with an elevated PSA were pretreated for 2 wk with the dual 5a-reductase inhibitor dutasteride before systematic prostate biopsy and CECD-targeted prostate biopsy was performed. The results of this study demonstrate the qualitative reduction of prostatic blood flow after shortterm oral therapy with dutasteride. A reduction of blood flow was already observed after 7 d and a further reduction was observed after 14 d of medication intake. These results confirm the recent findings of Ives et al [9], who found a reduction in visible Doppler US flow in all areas of the prostate after short-term therapy with dutasteride. As in their study we believe that the reduction is likely due to rapid short-term alterations in blood flow that are similar to the decreased microvessel densities previously reported to occur in patients treated with finasteride [9]. A previous study correlated whole-mount prostatectomy specimens with contrast-enhanced imaging
4 european urology 53 (2008) Fig. 1 Transverse ultrasound (US) images of prostate in 74-yr-old man with an elevated prostate-specific antigen level. Contrast-enhanced colour Doppler (CECD) US images through the midgland obtained (A) at baseline, (B) after 1 wk, and (C) after 2 wk of dutasteride therapy. The baseline images show increased CECD US flow at the right side of the gland with suspicion of prostate cancer. The posttreatment images show reduced overall CECD US flow after 1 wk and even absent after 2 wk of treatment. of the microbubble agent Sonazoid (Amersham Health, Oslo, Norway). Thirty-one foci of cancer were correlated between contrast-enhanced sonography and whole-mount pathologic inspection. Contrastenhanced imaging doubled the sensitivity for detection of cancer in the PZ of the prostate but did not improve the detection of inner gland cancer. The contrast-enhanced detection of cancers in the inner gland was limited by intense enhancement in areas of BPH. False-positive diagnoses of prostate cancer were suggested in both the inner and outer parts of the gland in areas of benign hyperplasia [10]. The results of this and other previous investigations have indicated that CECD US is only minimally better than conventional grey-scale US for distinguishing benign from malignant tissue [11]. The poor discrimination of benign from malignant tissue is due in part to the CECD signal arising from areas of benign disease such as BPH [12]. Therefore, given the association of false-positive areas of enhancement with BPH, one might expect to improve the specificity of CECD by pretreatment with a 5a-reductase inhibitor to suppress perfusion to areas of BPH. BPH nodules normally develop in the TZ or in the periurethral tissue, but BPH has also been identified at pathologic evaluation of the PZ [10,13]. In this small study, as mentioned above, 2-wk therapy with dutasteride reduced visible CECD flow in all areas of the prostate. It seems that dutasteride reduces
5 116 european urology 53 (2008) prostatic blood flow in benign tissue, whereas cancerous areas are still hypervascular after a 14-d intake of dutasteride. Twelve patients (33.3%) in our cohort were found to have suspicious blood flow and prostate cancer, and six cancers (16.6%) were detected solely by CECD-targeted biopsy. Prostatitis is also often considered an important cause of false-positive results at color Doppler US imaging of the prostate [10]. Interestingly in the present study prostatitis was not a significant cause of false-positive diagnoses with contrast enhancement. These findings match previous reported data from Halpern et al [14]. Our result suggests that the CECD signal associated with prostatitis and also benign prostate tissues is suppressed by dutasteride. In a previous trial, 11 subjects before prostate biopsy were evaluated by grey scale, colour, and power Doppler at baseline and weekly for up to 3 wk while taking the 5a-reductase inhibitor dutasteride (0.5 mg/d) [9]. Doppler flow suppression occurred in all 11 subjects after 1 wk ( p < 0.01). Further suppression was noted after 2 wk in 8 subjects ( p = 0.04). Flow suppression was greatest in the PZ and least obvious in the periurethral zone. Cancer was detected in 20% (8 of 40) of targeted cores and 7.6% (5 of 66) of sextant cores. Cancer was detected in 4 subjects by targeted biopsy and in 3 of 4 by SB. In the 4 men with cancer, targeted cores were 5.9 times more likely to be positive ( p = 0.027). Selective suppression of flow in benign tissue was observed in 2 of the 4 men with cancer. They concluded that shortterm dutasteride therapy reduces Doppler US flow in the prostate and may improve depiction of hypervascular cancer. They used Doppler US for blood flow evaluation of the prostate, whereas in our approach CECD has been used. CECD has shown to be more sensitive to slow flow and flow in small vessels by increasing the signal-to-noise ratio. This might further explain the better differentiation between benign and malignant prostate tissue. Our study demonstrates the reduction of prostatic blood flow in normal prostate, BPH, and prostatitis after short-term oral therapy with dutasteride, whereas cancerous areas are still hypervascular after a 14-d intake of dutasteride. Therefore, premedication with dutasteride seems promising to improve prostate cancer detection by using CECD US. This study has several limitations of which only the main ones are discussed. This had only a small study population, intraobserver and interobserver variability was not evaluated, no correlations were made with final radical prostatectomy specimens, and the CECD blood flow rating was subjectively measured. In the SB approach TZ biopsies have been performed, although a previous study by Pelzer et al suggested that in participants of a PSA screening program TZ biopsies do not improve prostate cancer detection rate and are therefore unnecessary [15]. Further, only the short-term therapy over 2 wk with dutasteride is reported; long-term effects are unknown. Therefore, further studies are necessary. 5. Conclusions Premedication with dutasteride seems promising to improve prostate cancer detection by using CECD US. Conflicts of interest There is no conflict of interest. References [1] Aus G, Abbou CC, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48: [2] Aarnink RG, Beerlage HP, De La Rosette JJ, Debruyne FM, Wijkstra H. Transrectal ultrasound of the prostate: innovations and future applications. J Urol 1998;159: [3] Kravchick S, Cytron S, Peled R, Altshuler A, Ben-Dor D. Using gray-scale and two different techniques of color Doppler sonography to detect prostate cancer. Urology 2003;61: [4] Frauscher F, Klauser A, Volgger H, et al. Comparison of contrast enhanced color Doppler targeted biopsy with conventional systematic biopsy: impact on prostate cancer detection. J Urol 2002;167: [5] Pelzer A, Bektic J, Berger AP, et al. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005;173: [6] Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol 2002;168: [7] Hochberg DA, Basillote JB, Armenakas NA, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 2002;167: [8] Leventis AK, Shariat SF, Utsunomiya T, Slawin KM. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. Prostate 2001;46: [9] Ives EP, Gomella LG, Halpern EJ. Effect of dutasteride therapy on Doppler US evaluation of prostate: preliminary results. Radiology 2005;237:
6 european urology 53 (2008) [10] Halpern EJ, McCue PA, Aksnes AK, Hagen EK, Frauscher F, Gomella LG. Contrast-enhanced US of the prostate with Sonazoid: comparison with whole-mount prostatectomy specimens in 12 patients. Radiology 2002;222: [11] van Moerkerk H, Heijmink SW, Hulsbergen-v.d. Kaa CA, Barentsz JO, Witjes JA. Computerized three-dimensional localization of prostate cancer using contrast-enhanced power Doppler and clustering analysis. Eur Urol 2006; 50:762 8, discussion [12] Halpern EJ, Rosenberg M, Gomella LG. Prostate cancer: contrast-enhanced US for detection. Radiology 2001;219: [13] Hamper UM, Sheth S, Walsh PC, Holtz PM, Epstein JI. Stage B adenocarcinoma of the prostate: transrectal US and pathologic correlation of nonmalignant hypoechoic peripheral zone lesions. Radiology 1991;180: [14] Halpern EJ, Ramey JR, Strup SE, Frauscher F, McCue P, Gomella LG. Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005;104: [15] Pelzer AE, Bektic J, Berger AP, et al. Are transition zone biopsies still necessary to improve prostate cancer detection? Results from the Tyrol Screening Project. Eur Urol 2005;48:916 21, discussion 921.
Effect of Dutasteride Therapy on Doppler US Evaluation of Prostate: Preliminary Results 1
Genitourinary Imaging Elizabeth P. Ives, MD Leonard G. Gomella, MD Ethan J. Halpern, MD Published online 10.1148/radiol.2371041543 2005; 237:197 201 Abbreviations: BPH benign prostatic hyperplasia PSA
More informationProstate Cancer 3/15/2017. CEUS of the Prostate. The Prostate Cancer Screening Dilemma Data. Incidence: 161,360 Deaths: 26,730
Prostate Cancer CEUS of the Prostate 2017 Data Incidence: 161,360 Deaths: 26,730 Third leading cause of cancer death in men (after lung & Professor of Radiology & Urology colon Ca) Co-Director, Jefferson
More informationAdvances in Ultrasound for the Detection of Prostate Cancer
Ultrasound Quarterly Vol. 18, No. 2, pp. 135 142 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Advances in Ultrasound for the Detection of Prostate Cancer Ferdinand Frauscher, M.D.,* Andrea Klauser,
More informationUltrasound of prostate cancer: recent advances
Eur Radiol (2008) 18: 707 715 DOI 10.1007/s00330-007-0779-7 UROGENITAL Leo Pallwein Michael Mitterberger Alexandre Pelzer Georg Bartsch Hannes Strasser Germar M. Pinggera Friedrich Aigner Johann Gradl
More informationAward Number: DAMD TITLE: Intermittent Ultrasound Imaging of Prostate Cancer. PRINCIPAL INVESTIGATOR: Ethan J. Halpem, M.D.
AD Award Number: DAMD17-01-1-0061 TITLE: Intermittent Ultrasound Imaging of Prostate Cancer PRINCIPAL INVESTIGATOR: Ethan J. Halpem, M.D. CONTRACTING ORGANIZATION: Jefferson Medical College Philadelphia,
More informationJMSCR Vol 05 Issue 03 Page March 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i3.135 Diagnosis of Carcinoma Prostate Based
More informationContrast-Enhanced Ultrasound and Prostate Cancer; A Multicentre European Research Coordination Project
european urology 54 (2008) 982 993 available at www.sciencedirect.com journal homepage: www.europeanurology.com Review Prostate Cancer Contrast-Enhanced Ultrasound and Prostate Cancer; A Multicentre European
More informationContrast-enhanced ultrasonography for the detection and characterization of prostate cancer: Correlation with microvessel density and Gleason score
Clinical Radiology 66 (2011) 732e737 Contents lists available at ScienceDirect Clinical Radiology journal homepage: www.elsevierhealth.com/journals/crad Original Paper Contrast-enhanced ultrasonography
More informationUsing Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer
Using Gray-Scale and Color and Power Doppler Sonography to Detect Prostatic Cancer Ethan J. Halpern 1 Stephen E. Strup 2 OBJECTIVE. We performed a prospective study to assess gray-scale and color and power
More informationTHE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE BIOPSIES IN IMPROVING THE DIAGNOSTIC ABILITY IN PROSTATE CANCER
Clinical Urology Brazilian Journal of Urology Official Journal of the Brazilian Society of Urology Vol. 27 (3): 222-226, May - June, 2001 THE SIGNIFICANCE OF HYPOECHOIC LESION DIRECTED AND TRANSITION ZONE
More informationContrast-Enhanced Harmonic Ultrasonography for the Assessment of Prostate Cancer Aggressiveness: a Preliminary Study
Contrast-Enhanced Harmonic Ultrasonography for the ssessment of Prostate Cancer ggressiveness: a Preliminary Study Yunkai Zhu, MD 1 Yaqing Chen, MD 1 Jun Jiang, MD 1 Ren Wang, MD 2 Yongchang Zhou, MD 2
More informationThe Value and Limitations of Contrast-enhanced Ultrasound in Detection of Prostate Cancer
The Value and Limitations of Contrast-enhanced Ultrasound in Detection of Prostate Cancer ARTA STRAZDIŅA 1, GAIDA KRŪMIŅA 1 and MĀRIS SPERGA 2 1 Department of Radiology, Eastern Clinical University Hospital,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationThe TRUS guided prostate extended biopsy in the detection of prostate cancer
Mædica - a Journal of Clinical Medicine ORIGIN RIGINAL PAPERS The TRUS guided prostate extended biopsy in the detection of prostate cancer Assoc. Prof. V. AMBERT, MD, PhD; A. ATEIA, MD; I. CHIRA, MD, PhD;
More informationReal-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images
Real-time Elastography for the Diagnosis of Prostate Cancer: Evaluation of Elastographic Moving Images Tomoaki Miyagawa 1, Masakazu Tsutsumi 2, Takeshi Matsumura 3, Natsui Kawazoe 2, Satoru Ishikawa 2,
More informationAre extended biopsies really necessary to improve prostate cancer detection?
(2003) 6, 250 255 & 2003 Nature Publishing Group All rights reserved 1365-7852/03 $25.00 www.nature.com/pcan Are extended biopsies really necessary to improve prostate cancer detection? R Damiano*,1, R
More informationProstate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144
Prostate MRI Hamidreza Abdi, MD,FEBU Post Doctoral Fellow Vancouver Prostate Centre UBC Department of Urologic Sciences May-20144 Objectives: Detection of prostate cancer the need for better imaging What
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21761
More informationTransrectal ultrasound-guided biopsy for the diagnosis of prostate cancer
Transrectal ultrasound-guided for the diagnosis of prostate cancer Adrian Haşegan Clinica de Urologie, Spitalul Clinic Judeţean de Urgenţă Sibiu Facultatea de Medicină Sibiu Abstract Transrectal ultrasound-guided
More informationeuropean urology 54 (2008)
european urology 54 (2008) 1354 1362 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Evaluation of Prostate Cancer Detection with Ultrasound Real-Time Elastography:
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationThe Journal of International Medical Research 2011; 39:
The Journal of International Medical Research 2011; 39: 256 266 Evaluation of Diffusion-weighted Magnetic Resonance Imaging and Contrast-enhanced Harmonic Ultrasonography in Detection and Location of Prostate
More informationThe utility of transrectal sonoelastography in preoperative prostate cancer assessment
Original papers Medical Ultrasonography 2012, Vol. 14, no. 3, 182-186 The utility of transrectal sonoelastography in preoperative prostate cancer assessment Steffen Rausch 1, Wibke Alt 2, Hartmut Arps
More informationHypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings
Hypoechoic Rim of Chronically Inflamed Prostate, as Seen at TRUS: Histopathologic Findings Hak Jong Lee, MD 1 Ghee Young Choe, MD 2 Chang Gyu Seong, MD 3 Seung Hyup Kim, MD 4 Index terms: Prostate Prostate,
More informationMRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review
MRI-targeted, transrectal ultrasound-guided prostate biopsy for suspected prostate malignancy: A pictorial review Poster No.: C-1208 Congress: ECR 2014 Type: Educational Exhibit Authors: J. Murphy, M.
More information11/10/2015. Prostate cancer in the U.S. Multi-parametric MRI of Prostate Diagnosis and Treatment Planning. NIH estimates for 2015.
Multi-parametric MRI of Prostate Diagnosis and Treatment Planning Temel Tirkes, M.D. Associate Professor of Radiology Director, Genitourinary Radiology Indiana University School of Medicine Department
More informationProstate biopsy: MR imaging to the rescue
Prostate biopsy: MR imaging to the rescue Poster No.: C-1855 Congress: ECR 2014 Type: Educational Exhibit Authors: N. V. V. B. Marques 1, J. Ip 1, A. Loureiro 2, J. Niza 1, M. Palmeiro 2, Keywords: DOI:
More informationIntroduction. HP Beerlage 1 *, RG Aarnink 1, ETh Ruijter 2, JA Witjes 1, H Wijkstra 1, CA van de Kaa 2, FMJ Debruyne 1 & JJMCH de la Rosette 1
(2001) 4, 56±62 ß 2001 Nature Publishing Group All rights reserved 1365±7852/01 $15.00 www.nature.com/pcan Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology
More informationTransrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital
R E V I E W A R T I C L E Transrectal Ultrasound for Prostate Cancer: Perspectives from National Cheng Kung University Hospital Yuh-Shyan Tsai 1,2, Chia-Horng Chen 3, Yi-Hsiang Lin 4, Tzong-Shin Tzai 1
More informationOutline (1) Outline (2) Concepts in Prostate Pathology. Peculiarities of Prostate Cancer. Peculiarities of Prostate Cancer
Concepts in Prostate Pathology Murali Varma Cardiff, UK wptmv@cf.ac.uk Sarajevo Nov 2013 Outline (1) Peculiarities of prostate cancer Peculiarities of prostate needle biopsy Needle bx vs. TURP Prostate
More informationDiffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence After Radical Prostatectomy: Initial Experience
EUROPEAN UROLOGY 61 (2012) 616 620 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Study of the Month Diffusion-Weighted Magnetic Resonance Imaging Detects Local Recurrence
More informationDetection of prostate cancer by MR-ultrasound fusion guided biopsy
Detection of prostate cancer by MR-ultrasound fusion guided biopsy Poster No.: C-0761 Congress: ECR 2014 Type: Scientific Exhibit Authors: T. Durmus, C. Stephan, T. Slowinski, A. Thomas, A. Maxeiner, B.
More informationThe Relationship between Prostate Inflammation and Lower Urinary Tract Symptoms: Examination of Baseline Data from the REDUCE Trial
european urology 54 (2008) 1379 1384 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia The Relationship between Prostate Inflammation and Lower Urinary
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationINTEROBSERVER VARIATION OF PROSTATIC VOLUME ESTIMATION WITH DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS WITH DIFFERENT EXPERIENCES
Clinical Urology International Braz J Urol Official Journal of the Brazilian Society of Urology DIGITAL RECTAL EXAMINATION BY UROLOGICAL STAFFS Vol. 30 (6): 466-471, November - December, 2004 INTEROBSERVER
More informationGetting to Diagnosis. Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust
Getting to Diagnosis Debbie Victor Uro-Oncology CNS Royal Cornwall Hospitals Trust GP Visit Symptoms Reduced urinary flow Difficulty starting/stopping Urgency Frequency Nocturia Because a friend/relative
More informationProstate-Specific Antigen (PSA) Test
Prostate-Specific Antigen (PSA) Test What is the PSA test? Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the
More informationExtended 12-Core Prostate Biopsy Increases Both the Detection of Prostate Cancer and the Accuracy of Gleason Score
european urology xxx (2005) xxx xxx available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Extended 12-Core Prostate Biopsy Increases Both the Detection of Prostate
More informationSerum Prostate-Specific Antigen as a Predictor of Prostate Volume in the Community: The Krimpen Study
european urology 51 (2007) 1645 1653 available at www.sciencedirect.com journal homepage: www.europeanurology.com Benign Prostatic Hyperplasia Serum Prostate-Specific Antigen as a Predictor of Prostate
More informationProstate Cancer DFP Case of the Week
Prostate Cancer DFP Case of the Week Antonio C. Westphalen, MD PhD Clinical Prostate MR Imaging Program, Director Associate Professor of Radiology and Urology University of California, San Francisco Case
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationProstate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017
Prostate cancer ~ diagnosis and impact of pathology on prognosis ESMO 2017 Dr Puay Hoon Tan Division of Pathology Singapore General Hospital Prostate cancer (acinar adenocarcinoma) Invasive carcinoma composed
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationComputer simulated additional deep apical biopsy enhances cancer detection in palpably benign prostate gland
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd? 200613?12901295Original ArticleAdditional apical biopsy in prostatic gland
More informationDoes normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
Original Article Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy? Sherif Azab 1, Ayman Osama 2, Mona Rafaat 3 1 Urology Department, Faculty
More informationProstate MRI. Overview. Introduction 2/20/2015. Prostate cancer is most frequently diagnosed noncutaneous cancer in males (25%)
Prostate MRI John Bell, MD Introduction Prostate Cancer Screening Staging Anatomy Prostate MRI overview Functional MRI Multiparametric Approach Indications Example Cases Overview Introduction Prostate
More informationor more transrectal ultrasonography (TRUS)-guided ng/ml and 39% if it was 20.0 ng/ml. of >10 ng/ml have prostate cancer [3], many other
BJU International (1999), 83, 34 38 Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? G.C. DURKAN
More informationDo 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?
european urology supplements 5 (2006) 752 757 available at www.sciencedirect.com journal homepage: www.europeanurology.com Do 5a-Reductase Inhibitors Alter Prostate Cancer Detection and What Are the Implications?
More informationProstate MRI: Not So Difficult. Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX
Prostate MRI: Not So Difficult Neil M. Rofsky, MD, FACR, FSCBTMR, FISMRM Dallas, TX What is the biggest barrier to your practice incorporating prostate MRI? 1) I don t know how to read the cases 2) I don
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2018 Origination: 8/2006 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas
More informationCancer. Description. Section: Surgery Effective Date: October 15, 2016 Subsection: Original Policy Date: September 9, 2011 Subject:
Subject: Saturation Biopsy for Diagnosis, Last Review Status/Date: September 2016 Page: 1 of 9 Saturation Biopsy for Diagnosis, Description Saturation biopsy of the prostate, in which more cores are obtained
More informationMini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano
Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it
More informationPROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment
PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.
More informationTHE UROLOGY GROUP
THE UROLOGY GROUP www.urologygroupvirginia.com 1860 Town Center Drive Suite 150/160 Reston, VA 20190 703-480-0220 19415 Deerfield Avenue Suite 112 Leesburg, VA 20176 703-724-1195 224-D Cornwall Street,
More information10/2/2018 OBJECTIVES PROSTATE HEALTH BACKGROUND THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION
THE PROSTATE HEALTH INDEX PHI*: BETTER PROSTATE CANCER DETECTION Lenette Walters, MS, MT(ASCP) Medical Affairs Manager Beckman Coulter, Inc. *phi is a calculation using the values from PSA, fpsa and p2psa
More informationHow Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?
More informationMR-US Fusion Guided Biopsy: Is it fulfilling expectations?
MR-US Fusion Guided Biopsy: Is it fulfilling expectations? Kenneth L. Gage MD, PhD Assistant Member Department of Diagnostic Imaging and Interventional Radiology 4 th Annual New Frontiers in Urologic Oncology
More informationInpyeong Hwang, Sang Youn Kim, Jeong Yeon Cho, Myoung Seok Lee, Seung Hyup Kim
The diagnostic ability of an additional midline peripheral zone biopsy in transrectal ultrasonography-guided 12-core prostate biopsy to detect midline prostate cancer Inpyeong Hwang, Sang Youn Kim, Jeong
More informationDiagnostic TRUS Elastography of the Prostate
Diagnostic TRUS Elastography of the Prostate George Zacharopoulos Department of Diagnostic Ultrasound Hygeia Hospital Athens, Greece Prostate HI-RTE Why we need Elastography Better Detection of possible
More informationDIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE
32, 4, 2010, 3.,.. DIAGNOSIS OF NONSPECIFIC GRANULOMATOUS PROSTATITIS IN PATIENTS UNDERGOING PROSTATE BIOPSY UNDER TRANSRECTAL ULTRASOUND GUIDANCE N. Smilov, N. Koleva and I. Lozev Medical Institute Ministry
More informationThe Clinical Potential of Pretreatment Serum Testosterone Level to Improve the Efficiency of Prostate Cancer Screening
european urology 51 (2007) 375 380 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer The Clinical Potential of Pretreatment Serum Testosterone Level to Improve
More informationValue of Power Doppler and 3D Vascular Sonography as a Method for Diagnosis and Staging of Prostate Cancer
European Urology European Urology 44 (2003) 21 31 Value of Power Doppler and 3D Vascular Sonography as a Method for Diagnosis and Staging of Prostate Cancer J.L. Sauvain a,*, P. Palascak b, D. Bourscheid
More informationCan Color Doppler Sonography Aid in the Prediction of Malignancy of Thyroid Nodules?
Article Can Color Doppler Sonography Aid in the Prediction of Malignancy of Thyroid Nodules? Mary C. Frates, MD, Carol B. Benson, MD, Peter M. Doubilet, MD, PhD, Edmund S. Cibas, MD, Ellen Marqusee, MD
More informationThe role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination
The role of T2-weighted imaging in detecting prostate cancer of the central zone in 3T multiparametric magnetic resonance examination Poster No.: C-2317 Congress: ECR 2014 Type: Scientific Exhibit Authors:
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationIntroduction. Growths in the prostate can be benign (not cancer) or malignant (cancer).
This information was taken from urologyhealth.org. Feel free to explore their website to learn more. Another trusted website with good information is the national comprehensive cancer network (nccn.org).
More informationSTUDY OF PROSTATIC LESION FOR A PERIOD OF FIVE YEARS
Page222 IJPBS Volume 4 Issue 2 APR-JUN 2014 222-226 Research Article Biological Sciences STUDY OF PROSTATIC LESION FOR A PERIOD OF FIVE YEARS B. Rajashekar Reddy 1, Rameswarapu Suman Babu 1 and Sujatha.P*
More informationAutomatic detection of prostate cancer using quantitative perfusion parameters in contrast-enhanced ultrasound.
Automatic detection of prostate cancer using quantitative perfusion parameters in contrast-enhanced ultrasound. Poster No.: C-1798 Congress: ECR 2016 Type: Scientific Exhibit Authors: M. Skendi, A. KHAIROUNE,
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationSaturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer
Saturation Biopsy for Diagnosis and Staging and Management of Prostate Cancer Policy Number: 7.01.121 Last Review: 2/2019 Origination: 8/2006 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas
More informationBJUI. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer?
. JOURNAL COMPILATION 2010 BJU INTERNATIONAL Urological Oncology FOLLOW-UP OF MEN WITH AN ELEVATED PCA3 SCORE AND A NEGATIVE BIOPSY REMZI ET AL. BJUI BJU INTERNATIONAL Follow-up of men with an elevated
More informationRole of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53..46 Urological Oncology Role of Prostate-Specific Antigen Change Ratio at Initial Biopsy as a Novel Decision-Making Marker for Repeat Prostate Biopsy
More informationContribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate volume matter?
ORIGINAL ARTICLE Gulhane Med J 2018;60: 14-18 Gülhane Faculty of Medicine 2018 doi: 10.26657/gulhane.00010 Contribution of prostate-specific antigen density in the prediction of prostate cancer: Does prostate
More informationINTRADUCTAL LESIONS OF THE PROSTATE. Jonathan I. Epstein
INTRADUCTAL LESIONS OF THE PROSTATE Jonathan I. Epstein Topics Prostatic intraepithelial neoplasia (PIN) Intraductal adenocarcinoma (IDC-P) Intraductal urothelial carcinoma Ductal adenocarcinoma High Prostatic
More informationZonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy
european urology 51 (2007) 949 955 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical
More informationProstate Cancer Screening Guidelines in 2017
Prostate Cancer Screening Guidelines in 2017 Pocharapong Jenjitranant, M.D. Division of Urology, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital Prostate Specific Antigen (PSA) Prostate
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationAdvances in Bioscience and Clinical Medicine ISSN:
Advances in Bioscience and Clinical Medicine ISSN: 2203-1413 www.abcmed.aiac.org.au Original Paper Role of Duplex Ultrasound in Diagnosis of Prostate Cancer and Localization for Biopsy Iman Yazdaninia,
More informationMRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know
MRI in the Enhanced Detection of Prostate Cancer: What Urologists Need to Know Michael S. Cookson, MD, FACS Professor and Chair Department of Urology Director of Prostate and Urologic Oncology University
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationEAU GUIDELINES POCKET EDITION 3
EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books
More informationThe population of subjects which was statistically analyzed was the Intent-to-Treat population
Study No.: ARIB3003 (Year 1) Title: A Randomized, Double-Blind, Placebo-Controlled, Two-Year Parallel-Group Study of the Efficacy and Safety of GI198745 in the Treatment and Modification of Progression
More informationEUROPEAN UROLOGY 58 (2010)
EUROPEAN UROLOGY 58 (2010) 551 558 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Prostate Cancer Prevention Trial and European Randomized Study of Screening
More informationBJUI. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer
2008 The Authors. Journal compilation 2008 BJU International Original Article TEMPLATE-BASED PROSTATE BIOPSY SYSTEM MEGWALU et al. BJUI BJU INTERNATIONAL Evaluation of a novel precision template-guided
More informationRadical Perineal Prostatectomy and Simultaneous Extended Pelvic Lymph Node Dissection via the Same Incision
european urology 52 (2007) 384 388 available at www.sciencedirect.com journal homepage: www.europeanurology.com Surgery in Motion Radical Perineal Prostatectomy and Simultaneous Extended Pelvic Lymph Node
More informationProstate CancerTest TM. Test Report
Test Report Patient Information Requisition Number Patient Name ID Number Date of Birth Gender M Patient Phone Number Patient E-mail Name of Lab Lab Phone Number Name of Physician Date of Collection Date
More informationBPH with persistently elevated PSA 아주대학교김선일
BPH with persistently elevated PSA 아주대학교김선일 PSA in BPH: present status AUA & EAU BPH guideline: PSA: recommended test AUA practice guideline committee. J Urol 2003;170:530 Madersbacher. Eur Urol 2004;46:547
More informationDepartment of Urology, II Clinic, Ankara Numune Education and Research Hospital, Ankara, Turkey 2
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 252846, 5 pages doi:10.5402/2012/252846 Clinical Study The Correlation between Diffusion-Weighted Imaging and Histopathological
More informationMEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND (TRUS)
MEDICAL POLICY SUBJECT: TRANSRECTAL ULTRASOUND 06/16/05, 05/18/06, 03/15/07, 02/21/08 PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under
More informationA re-audit of Prostate biopsies from January to December 2010 and 2013.
A re-audit of Prostate biopsies from January to December 2010 and 2013. Dr. M S Siddiqui Consultant Histopathologist University Hospital of North Tees Stockton on Tees. Objectives To assess and compare
More information6 UROLOGICAL CANCERS. 6.1 Key Points
6 UROLOGICAL CANCERS 6.1 Key Points Prostate Cancer Commonest cancer in males in Scotland Approximately 99% of cases occur in men aged > 50 years About 40% of cases present in men aged < 70 years when
More informationUltrasonographically Guided Biopsy of the Prostate Gland
Review Article Ultrasonographically Guided Biopsy of the Prostate Gland Andrew L. Altman, MD, Martin I. Resnick, MD Abbreviations BPH, benign prostatic hyperplasia; PIN, prostatic intraepithelial neoplasia;
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationRenal Aplastic Dysplasia and Ipsilateral Ectopic Ureter Obstructing the Seminal Via: A Possible Cause of Male Infertility
european urology 52 (2007) 268 272 available at www.sciencedirect.com journal homepage: www.europeanurology.com Case Study of the Month Renal Aplastic Dysplasia and Ipsilateral Ectopic Ureter Obstructing
More informationThuchchai Pipitpanpipit, M.D.
ARC Journal of Urology Volume 1, Issue 2, 2016, PP 15-19 www.arcjournals.org Prospective Randomized Controlled Study of the Results of Medication with Oral versus Oralcefixime to Prevent Transient Bacteraemia
More information